Heparin therapy delays Alzheimer’s diagnosis by one to two years, offering potential insights into new protective treatments. Large-scale health records show a promising association between the anticoagulant and delayed dementia onset.
Amgen’s Leah Christl makes the case to keep the interchangeability designation for biosimilars
Amgen and its portfolio of 11 biosimilars is standing behind interchangeability, saying the designation should not be rescinded and that the FDA needs to retain
September 13, 2023